ClinicalTrials.gg
CompletedNCT02064920Updated Oct 12, 2018Results posted

Computerized Cognition Testing in Participants With Mild Alzheimer's Disease (AD) Treated With Donepezil (MK-0000-318)

A Phase 2 interventional study of Placebo and Donepezil in Alzheimer's Disease, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-10-12.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
55 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing donepezil in Alzheimer Disease — 2 open to participants now, 2 under way, 1 of them phase 3. Donepezil · Alzheimer Disease.

Enrollment
43rd of 58
36 · median 79
Started
2014
with 5 others
Phase 2
4 of 60
none open now
Registered
40th of 60
by date
Lead sponsor
3 of 60
Merck Sharp & Dohme LLC

Among the 60 studies testing donepezil in Alzheimer Disease, this one is the 43rd largest by enrollment of the 58 interventional ones that give a count, is one of 6 that started in 2014, is one of 4 in phase 2, and was the 40th registered.

Alzheimer Disease

3,970 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

2 of the 60 studies testing donepezil in Alzheimer Disease are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About donepezil

Donepezil: first FDA approval 1996 (ARICEPT). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.

This study: 55 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing donepezil in Alzheimer Disease, or all of them as a file.
02

Study summary

This study aims to determine whether the Cogstate testing battery can detect improvements in cognitive function in participants with mild AD. The primary hypothesis is that for one of the Cogstate battery tests, One Card Learning (OCL), the standard deviation associated with the change from baseline in OCL measurements after 12 weeks of donepezil and placebo treatments is =\<0.1

03

Conditions studied

  • Alzheimer's Disease

Browse trials for

04

Who can participate

Ages eligible
55 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets listed criteria for a diagnosis of probable AD
  • Has a clearly documented history either in medical records or from an informant of cognitive decline over at least 6 months
  • Has a reliable partner/caregiver who is willing to provide input by participating in assessments
  • Has results of a physical examination and clinical laboratory tests within normal or clinically acceptable limits
  • Can communicate with trial staff acceptably, possesses the ability to respond verbally to questions, follow instructions, complete questionnaires, and adhere to visit schedules
  • Can read at a 9th grade level or equivalent, and has an acceptable history of academic achievement and/or employment
  • Has a magnetic resonance imaging (MRI) scan that rules out non-AD conditions contributing to cognitive dysfunction
  • Capably performs the CogState screening battery
  • Has adequate visual acuity and function
  • Females are not of

Exclusion criteria

Exclusion Criteria:

  • Has ever received acetylcholinesterase inhibitors, memantine, or other symptomatic AD treatment including approved medical foods
  • Has an uncontrolled, medical condition or situation within 3 months prior to screening
  • Has had major surgery within 3 months prior to screening
  • Has tested positive for (HIV) or has evidence of an active infection
  • Has a history of within the prior 5 years
  • Is unwilling or ineligible to undergo an MRI scan
  • Has a history of clinically important structural changes on screening MRI scan
  • Has a clinically important history of stroke or a diagnosis of vascular dementia
  • Has evidence of a clinically relevant non-AD neurological disorder
  • Has a history of head trauma, or serious infectious disease affecting the brain within the prior 3-5 years
  • Has evidence of a clinically relevant or unstable psychiatric disorder, excepting major depression in remission
  • Has evidence of a current episode of major depression
  • Has evidence of Type 4 or Type 5 Suicidal Ideation
  • Has clinically significant vitamin B12 or folate deficiency in the 6 months prior to screening
  • Is pregnant, attempting to become pregnant or is nursing children
  • Has used any drug or participated in any other clinical trial within the prior 30 days
  • Has a history of alcoholism or drug dependency/abuse within the last 5 years
  • Has a relative to donepezil including sick sinus syndrome, third degree heart block, active gastrointestinal (GI) bleeding, Zollinger-Ellison syndrome, uncontrolled peptic ulcer disease, or uncontrolled asthma
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo for donepezil hydrochloride capsule administered orally once a day for 16 weeks.

    Drug: Placebo

  • Experimental
    Donepezil

    During the first 4 weeks, participants received placebo for donepezil. Over the following 2 weeks, participants were treated with donepezil at 5 mg per day. Then, over the remaining 10 weeks were titrated to up to 10 mg per day donepezil based on tolerability.

    Drug: Placebo · Drug: Donepezil

Interventions

  • DrugPlacebo

    Placebo for donepezil hydrochloride capsule

  • 5 mg donepezil hydrochloride capsule.

    Also known as: Aricept

  • 10 mg donepezil hydrochloride capsule.

    Also known as: Aricept

06

What researchers measure

Primary outcomes

  1. One-card Learning (OCL) Measurement Over 12 Weeks of Treatment

    OCL is one of the Cogstate battery of tests, and is a continuous visual recognition task that assesses visual recognition, memory and attention using a pattern separation algorithm. OCL is a score defined as the arcsine transformation of the square root of the proportion of correct responses to 80 OCL questions. The score ranges from 0 to 1.5708 where a higher score means better performance.

    Time frame: Weeks 4, 8, 12 and 16

Secondary outcomes

  1. Percentage of Correct Responses in the OCL Task Over 12 Weeks of Treatment

    OCL is one of the Cogstate battery of tests, and is a continuous visual recognition task that assesses visual recognition, memory and attention using a pattern separation algorithm. The percentage of correct responses to 80 OCL questions is defined as the number of correct responses x 100 divided by the number of total responses; and ranges from 0 to 100, where 100 is best, and 0 is the worst outcome.

    Time frame: Weeks 4, 8, 12 and 16

07

Results

Posted Aug 1, 2017

Participant flow

Males and females with mild Alzheimer's Disease (AD) between the ages of 55 and 85 years (inclusive) were enrolled in this trial.

Participant flow — Overall Study
MilestonePlaceboDonepezil
Started630
Treated628
Completed521
Not completed19
Withdrew: Adverse event04
Withdrew: Physician decision01
Withdrew: Technical problems01
Withdrew: Withdrawal by subject13

Outcome measures

PrimaryOne-card Learning (OCL) Measurement Over 12 Weeks of Treatment

OCL is one of the Cogstate battery of tests, and is a continuous visual recognition task that assesses visual recognition, memory and attention using a pattern separation algorithm. OCL is a score defined as the arcsine transformation of the square root of the proportion of correct responses to 80 OCL questions. The score ranges from 0 to 1.5708 where a higher score means better performance.

Time frame:
Weeks 4, 8, 12 and 16
Reported as:
Mean · Score on a scale
One-card Learning (OCL) Measurement Over 12 Weeks of Treatment
Score on a scalePlaceboDonepezil
Week 4 (n = 5, 28)0.954 ± 0.0910.942 ± 0.112
Week 8 (n = 5, 22)0.822 ± 0.1790.969 ± 0.104
Week 12 (n = 5, 21)0.849 ± 0.1320.984 ± 0.118
Week 16 (n = 5, 21)0.961 ± 0.1230.993 ± 0.112
Statistical analysis
  • Placebo vs Donepezil · Change in sd from week 4 to week 16: 0.005 · 95% CI -0.031 to 0.039SD of average OCL repeated measurements after 12 weeks of treatment for Placebo + Donezepil treatment groups combined is hypothesized to be ≤ 0.1.
SecondaryPercentage of Correct Responses in the OCL Task Over 12 Weeks of Treatment

OCL is one of the Cogstate battery of tests, and is a continuous visual recognition task that assesses visual recognition, memory and attention using a pattern separation algorithm. The percentage of correct responses to 80 OCL questions is defined as the number of correct responses x 100 divided by the number of total responses; and ranges from 0 to 100, where 100 is best, and 0 is the worst outcome.

Time frame:
Weeks 4, 8, 12 and 16
Reported as:
Mean · Percentage of Corrrect Responses
Percentage of Correct Responses in the OCL Task Over 12 Weeks of Treatment
Percentage of Corrrect ResponsesPlaceboDonepezil
Week 4 (n = 5, 28)66.2 ± 8.364.9 ± 10.3
Week 8 (n = 5, 22)53.7 ± 17.167.4 ± 9.5
Week 12 (n = 5, 21)56.1 ± 12.768.6 ± 10.4
Week 16 (n = 5, 21)66.7 ± 11.669.5 ± 9.8

Adverse events

Collected over Up to Week 18 (approximately up to 129 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—0/6 (0%)3/6 (50%)
Donepezil—1/28 (3.6%)9/28 (32.1%)
Most frequent serious events
Most frequent serious events
EventPlaceboDonepezil
Chest painGeneral disorders0/61/28
Most frequent other events
Most frequent other events
EventPlaceboDonepezil
DiarrhoeaGastrointestinal disorders1/64/28
NasopharyngitisInfections and infestations1/60/28
Blood urea increasedInvestigations1/60/28
HeadacheNervous system disorders1/62/28
DizzinessNervous system disorders0/62/28
InsomniaPsychiatric disorders0/62/28

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboDonepezilTotal
Mean76.7 ± 8.672.7 ± 8.773.4 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDonepezilTotal
Female21517
Male41519
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Jul 2016, 26 months.

Results were first posted in Aug 2017, 1 year after primary completion.

Of 131 industry-sponsored phase 2 interventional studies under Alzheimer Disease, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 39. This study's 26 months is close to that.

Counting every sponsor, half of 258 studies reached it within 37 months; a quarter within 21 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2014
First posted
Feb 17, 2014
StartActual
Apr 22, 2014
Primary completionActual
Jul 13, 2016
CompletionActual
Jul 13, 2016
Results first posted
Aug 1, 2017
Last update
Oct 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02064920
Responsible party
Sponsor
First posted
Feb 17, 2014
Start date
Apr 22, 2014
Primary completion
Jul 13, 2016
Completion
Jul 13, 2016
Results posted
Aug 1, 2017
Last update
Oct 12, 2018

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Donepezil

Start the discussion